Weekly Analysts’ Ratings Changes for Bio-Techne (TECH)

Bio-Techne (NASDAQ: TECH) recently received a number of ratings updates from brokerages and research firms:

• 5/9/2025 – Bio-Techne had its price target lowered by analysts at UBS Group AG from $95.00 to $70.00. They now have a “buy” rating on the stock.
• 5/8/2025 – Bio-Techne had its price target lowered by analysts at Royal Bank of Canada from $72.00 to $63.00. They now have a “sector perform” rating on the stock.
• 5/8/2025 – Bio-Techne was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 5/8/2025 – Bio-Techne had its price target lowered by analysts at Stifel Nicolaus from $75.00 to $60.00. They now have a “hold” rating on the stock.
• 5/8/2025 – Bio-Techne had its price target lowered by analysts at Benchmark Co. from $95.00 to $75.00. They now have a “buy” rating on the stock.
• 4/17/2025 – Bio-Techne was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 4/9/2025 – Bio-Techne had its “sector weight” rating reaffirmed by analysts at KeyCorp.
• 4/4/2025 – Bio-Techne was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 3/26/2025 – Bio-Techne was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 3/18/2025 – Bio-Techne is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $75.00 price target on the stock.
• 3/18/2025 – Bio-Techne was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Bio-Techne Price Performance

Shares of NASDAQ:TECH opened at $49.98 on Monday. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. Bio-Techne Co. has a twelve month low of $46.01 and a twelve month high of $85.57. The stock’s 50 day moving average is $54.68 and its 200-day moving average is $66.21. The firm has a market capitalization of $7.90 billion, a price-to-earnings ratio of 50.48, a PEG ratio of 2.88 and a beta of 1.46.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. The business had revenue of $316.18 million during the quarter, compared to analyst estimates of $317.92 million. Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. Bio-Techne’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 EPS. Sell-side analysts forecast that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 30th. Investors of record on Monday, May 19th will be paid a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Monday, May 19th. Bio-Techne’s payout ratio is currently 32.32%.

Insider Transactions at Bio-Techne

In related news, Director Amy E. Herr sold 1,860 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $65.96, for a total transaction of $122,685.60. Following the completion of the transaction, the director now directly owns 1,976 shares in the company, valued at $130,336.96. The trade was a 48.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Bio-Techne

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TECH. CX Institutional bought a new stake in Bio-Techne during the first quarter worth about $27,000. UMB Bank n.a. grew its holdings in shares of Bio-Techne by 46.4% during the 4th quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Bio-Techne during the 4th quarter worth approximately $41,000. Federated Hermes Inc. purchased a new position in shares of Bio-Techne during the 1st quarter worth approximately $41,000. Finally, GeoWealth Management LLC purchased a new stake in shares of Bio-Techne in the 4th quarter worth approximately $43,000. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.